Our study not only elucidates a novel mechanism on the gut microbiota-derived BCAA that drives the communication between microbiota, liver and heart and affects DCM via FGF21, but also provides a potential therapeutic strategy for DCM by targeting the gut-liver-heart axis. The gene discussed is FGF21; the disease is familial dilated cardiomyopathy.